A review of fecal microbiota, live-jslm for the prevention of recurrent Clostridioides difficile infection

CONCLUSION: Fecal microbiota, live-jslm has consistently been shown in randomized trials to be safe and effective in reducing rCDI. Its approval marks the culmination of decades of work to identify, characterize, and refine the intestinal microbiome to create pharmaceutical products.PMID:38470061 | DOI:10.1093/ajhp/zxae066
Source: American Journal of Health-System Pharmacy : AJHP - Category: Drugs & Pharmacology Authors: Source Type: research